International Journal Publishing
INFLUENCE: International Journal of Science Review
Volume 6, No. 1, 2024
https://influence-journal.com/index.php/influence/index

Nanometer-Scale Drug Synthesis: Innovations in Pharmaceutical Nanotechnology

Maulida Fajriyah[1], Neng Rita Nurjannah[2], Nurul Ambardhani[3], Nanda Raudhatil Jannah[4]
[1] *Departement of Chemistry, Institute of Technology Bandung, Indonesia*
[2] *Sekolah Pascasarjana, Universitas Padjadjaran*
[3,4]*Study Program of Pharmacy, Faculty of Science and Technology, Universitas Muhammadiyah Bandung*
Email: maulida17002@mail.unpad.ac.id

Abstract. Nanometer-scale drug development represents a new era in pharmaceutical technology, promising significant improvements in the efficacy and safety of treatments. Nanotechnology innovations in drug synthesis offer the potential to address existing global health challenges, including drug resistance and difficult-to-treat chronic diseases. However, the synthesis process at the nanometer scale faces significant obstacles, including biocompatibility issues, unclear regulations, and technical challenges in production. This research aims to explore and identify strategies to overcome these challenges, as well as assess the potential of nanotechnology innovation in the development of new drugs. The research method used is a descriptive qualitative approach, with data sourced from relevant previous literature. The data collected is then processed to gain an in-depth understanding of the research subject. The conclusions of this study indicate that although the challenges in nanometer-scale drug synthesis are significant, the potential for nanotechnology innovation in pharmaceuticals is revolutionary. Effective strategies to overcome these challenges include the development of new synthesis methods, advances in characterization techniques, and close interdisciplinary collaboration. Policies and regulations that support innovation are urgently needed to facilitate the development and implementation of these new medicines. Finally, the future of nanometer-scale medicine depends on increasing access and desirability, taking into account ethics and safety in product development.

Keywords: *Drug Innovation, Nanotechnology, Drug Synthesis.*

A. INTRODUCTION

Rapid developments in science and technology have opened up new avenues in drug discovery and development. In recent decades, research and development in pharmaceuticals have been faced with increasingly complex challenges, including drug resistance, undesirable side effects, and barriers to efficient drug delivery. To overcome these challenges, researchers have sought new approaches that can improve treatment efficacy while minimizing risks to patients (Zhang et al., 2020). One of the most promising innovations in drug development is the application of nanotechnology. Nanotechnology, with its focus on manipulating matter at the nanometer scale, offers the possibility of creating more effective drug delivery systems, increasing drug solubility, and reducing side effects. However, despite this great potential, there are significant challenges that must be overcome, especially related to drug synthesis at the nanometer scale (Sahu et al., 2021).

The challenges in nanometer-scale drug synthesis are not only limited to technical and scientific aspects, but also include ethical, regulatory, and cost considerations. Drug development on this scale requires large investments in research and development, as well as sophisticated laboratory infrastructure. In addition, the safety and effectiveness aspects of nanometer drugs must be tested extensively to ensure that they do not pose new risks to patients. The increasing prevalence of chronic diseases and multidrug resistance (MDR) is one of the main driving factors in nanometer-scale drug research (Malik et al., 2023). Diseases such as cancer, diabetes, and cardiovascular disease require more innovative and effective treatment strategies. Nanometer-scale drugs offer the possibility to overcome several barriers in the

treatment of these diseases, such as improving drug delivery to target cells specifically, reducing required doses, and minimizing undesirable drug interactions (Pala et al., 2020).

The development of nanometer-scale drugs is also seen as a potential solution to the problem of drug shortages. By improving the efficiency of drug development and production processes, nanometer-scale drugs can help speed up the drug manufacturing process and reduce costs, making them more affordable and accessible to a wider population. Although the prospects for nanotechnology in drug development are very promising, there are still many obstacles to overcome (Park et al., 2022). From a scientific perspective, drug synthesis at the nanometer scale requires a deep understanding of the molecular dynamics and interactions between nanoparticles and biological systems. From a regulatory perspective, there needs to be a clear framework for the evaluation, approval, and monitoring of nanometer drugs to ensure their safety and effectiveness for patients (Dawson & Yan, 2021).

The sum of these challenges and opportunities highlights the importance of continued research in nanometer-scale drug synthesis. By understanding more deeply the potential and limitations of this technology, the scientific community can open the door to a new generation of treatments that are safer, more effective, and accessible to all levels of society.

B. LITERATURE REVIEW

1. Drug Synthetic

Drug synthesis is a process of producing drugs that can be applied on a large scale other than the synthesis of lead and analogs. Drug synthesis pathways are broadly classified as partially synthetic routes and fully synthetic routes. The partial synthetic route is often used in the synthesis of drugs and analogs as well as in drug manufacturing processes where a required compound has several chiral centers in its structure (Li et al., 2022). Meanwhile, the fully synthetic route is a synthesis process that is carried out starting from the preparation of starting materials, namely synthetic or natural, but only using standard organic synthesis methods to produce the desired product.

Several general considerations must be made before carrying out a synthesis, namely:

a) Starting materials must be cheap and available (Turcheniuk et al., 2021).
b) The reaction yield must be high. This is important when the synthetic pathway involves a large number of steps (Bell et al., 2021).
c) The resulting product must be relatively easy to isolate, purify, and identify (Coughlan et al., 2020).
d) The reaction must be stereospecific because it is often difficult and expensive to separate the enantiomers. However, the exclusive use of stereospecific reactions in drug-synthetic pathways is a condition that is often difficult to fulfill (Patti & Sanfilippo, 2020).
e) The reactions used in the synthesis reaction stage must be adaptable to large-scale production methods. The reactions used by researchers often use expensive reagents. Therefore, chemists are required to help develop pharmaceutical materials so that they can find cost-effective and simpler alternatives (Lovato et al., 2021).
f) Overall design. Can be used in several synthesis routes including; linear synthesis i.e. one step in the path is immediately followed by another step; Convergent synthesis is where two or more parts of a molecule are synthesized separately before being combined to form a target structure (Liu et al., 2022).
g) The synthesis strategy must be able to develop, among other things, using a breakthrough approach to find suitable starting materials, finding compounds with similar structures, modifying natural products, and divergence (modification) (Wainwright et al., 2022).
h) Use of protection groups. The design of synthetic pathways often requires reactions to be carried out at one center in the molecule as a primary process, while a second center is prevented from interfering with the primary process or undergoing similar undesired reactions (Rogge et al., 2021).

2. Nanotechnology

Nanotechnology can generally be defined as the technology of manipulating the size of a material from large to nano-sized. Nanotechnology is currently the most developed field of research in modern materials science. In nanotechnology, one thing that gets a lot of attention is nanoparticles (Khan et al., 2022). A material can be categorized as a nanoparticle if it has a nanoscale size ranging from 1 nanometer to 100 nanometers. Nanoparticles have many uses in various fields including health, cosmetics, the environment, textiles, and also catalysts. To make nanoparticles, metal synthesis is usually carried out using a medium and in a certain way (Barhoum et al., 2022).

The synthesis of these nanoparticles can be done in three ways, namely chemically, biologically, and physically. Chemically, nanoparticle synthesis is carried out by adding chemicals that function as stabilizers of nanoparticle size. This chemical synthesis produces toxins and can cause environmental pollution (Szczyglewska et al., 2023). Biological synthesis of nanoparticles is carried out by adding a synthesizing agent that comes from nature, from organisms to microorganisms. Examples include fungi, bacteria, and plants. Meanwhile, the physical synthesis of nanoparticles can be done by evaporation or condensation (Alsaiari et al., 2023).

In nanoparticle synthesis, the desired result is that the particles have the smallest possible size and have an irregular shape, where to obtain the desired result an agent is needed that can act as a reducing agent. The results obtained from the synthesis of these nanoparticles depend on the strength or weakness of the reducing agent used (Ijaz et al., 2020). The synthesis of nanoparticles carried out in this experiment was carried out chemically and biologically using microemulsion which acts as a medium for the synthesis process and is usually referred to as a micro nanoreactor and uses mangosteen peel extract and green tea as reducing agents which are of course environmentally friendly. Microemulsion is a mixture of surfactant, water, and oil (Salvador et al., 2021).

Because nanoparticles have a small particle size, they have several advantages, one of which is the ratio of surface area to particle volume and also high atomic activity on the particle surface so that the nature of the particles and their interactions with other materials can change (Ndolomingo et al., 2020). Nanoparticle synthesis currently needs to be improved because nanoparticles which are part of nanotechnology can be applied in various fields such as health, environment, food, and cosmetics. By applying these nanoparticles, the process will become easier and more profitable (Bahrulolum et al., 2021). In general, there are two ways/methods of nanoparticle synthesis, namely:

a) Top-down method. Nanoparticle synthesis using the top-down method can produce nanoparticles with a size of 10 nanometers to 100 nanometers. This nano size is obtained by reducing the size of a particle by applying an external force to a large material until the size changes to nano size and this method is only applied to materials with a solid phase. Top-down methods can be performed by cutting, grinding, and etching/etching at the nanoscale (Abid et al., 2022).
b) Bottom-up method. Synthesis of nanoparticles using the bottom-up method can produce nanostructures with a more homogeneous chemical composition, carried out by forming the nanoparticle structure by the atoms of a molecule. This bottom-up method can be carried out using two phases, namely the gas phase and the liquid phase. In the liquid phase, this can be done using the chemical reduction method, where the reducing agent, dispersing agent, reaction time, and temperature can be adjusted to obtain the desired shape and size of the nanoparticles (Escudero et al., 2021).

C. METHOD

This research will be carried out using a descriptive qualitative approach. This approach was chosen because it allows researchers to deeply explore and understand the complexity of

nanometer-scale drug synthesis processes, the challenges faced, as well as development and innovation strategies in pharmaceutical nanotechnology. The data used in this research comes from various results of previous research which still have relevance to this research. These data sources were selected for their ability to provide in-depth insights into recent developments and challenges faced in nanometer-scale drug synthesis, as well as the potential of nanotechnology innovations in improving drug efficacy and safety. When research data is successfully collected, then this data will be processed, so that the results of this research can be found. Through this approach, this research aims to generate a broader and deeper understanding of the dynamics of nanometer-scale drug development, with the hope of contributing to improved synthesis strategies, the development of new drugs, and the implementation of nanometer technology in pharmaceuticals.

D. RESULT AND DISCUSSION

A. Challenges in Nanometer Scale Drug Synthesis

In the world of pharmaceuticals and drug development, nanometer-scale drug synthesis promises a major revolution with the potential to increase treatment efficacy and reduce side effects. However, this journey towards innovation is not simple. One of the main challenges faced is the technical complexity involved in the synthesis process at the nanometer scale. Controlling the synthesis process on this scale requires extreme accuracy and care, where difficulties in achieving particle uniformity and formulation stability are frequent obstacles. Particle uniformity is essential to ensure that each dose of the drug provides consistent effects, while formulation stability determines the shelf life and effectiveness of the drug throughout use. This problem becomes more complicated when drugs must be designed to meet stringent biocompatibility requirements.

Biocompatibility is another critical consideration in the development of nanoparticles for medical applications. To be used successfully in the human body, nanoparticles must be able to interact with cells and tissues without causing adverse immune responses or toxicity. Challengingly, many materials at the nanometer scale behave differently than at the macroscale, with the potential for toxicity and immunogenicity not yet fully understood. This requires extensive research and testing to ensure that the nanoparticles are not only effective in delivering drugs but also safe for patients. Moreover, regulations governing the use of nanometer materials in medicine are still evolving, creating uncertainty for researchers and drug developers in ensuring their products meet the necessary safety standards.

Regulation and standardization are challenges in the evolution of nanometer-scale medicine. The need for strict regulations and standardization of production processes is essential to ensure drug quality and safety. However, the world of nanotechnology is still relatively new, and many aspects of regulation remain in a gray area. This demands ongoing dialogue between scientists, regulators, and other stakeholders to develop frameworks that support innovation while ensuring patient protection. These regulatory complexities not only slow down the drug development process but also add uncertainty to the process.

In addition to scientific and regulatory challenges, the cost of developing nanometer-scale drugs is also a major obstacle. Research and development in this area require significant investment, both in terms of time and financial resources. These high costs not only affect companies and research institutions looking to develop new technologies but also potentially limit the accessibility of drugs to the wider population. While nanometer medicines offer many benefits, their high prices can make them unaffordable for most patients, especially in developing countries where such innovations may be most needed. Therefore, finding ways to reduce development costs while maintaining drug safety and efficacy standards is one of the key challenges that must be overcome in realizing the full potential of nanometer-scale drugs.

Overall, nanometer-scale drug synthesis represents a new paradigm in drug development that promises to change the face of modern medicine. While the challenges remain significant,

continued breakthroughs in technology, regulation, and funding strategies may pave the way to fully exploit the potential of nanometer-scale medicines. With close collaboration between the scientific community, industry, regulators, and society, we can overcome these barriers and usher in a new era of drug therapies that are more effective, safe, and accessible to everyone.

B. Potential of Nanotechnology Innovation in Drug Synthesis

The potential of nanotechnology innovation in drug synthesis promises breakthroughs that could change the current treatment paradigm, offering solutions to several challenges faced by the pharmaceutical industry. By utilizing particles at the nanometer scale, we can see significant improvements in drug efficacy. One way nanotechnology achieves this is through increasing the solubility and bioavailability of drugs. Many drugs under development have limitations in solubility, which directly affects the body's ability to absorb and utilize them effectively. Nanoparticles can be designed to increase drug solubility, thereby allowing the drug to be better absorbed by the body, reaching therapeutic concentrations within the system more quickly and efficiently. This not only increases the efficacy of the drug but can also reduce the dose required, thereby reducing the possibility of side effects.

Furthermore, better drug delivery systems are becoming one of the main focuses in the application of nanotechnology. The ability to direct drugs specifically to target cells or tissues is one of the greatest advantages of nanotechnology. With specifically designed delivery systems, drugs can be released directly to the required location, minimizing interactions with uninvolved cells and tissues. This not only increases the effectiveness of therapy but also significantly reduces side effects, allowing safer and more tolerable drug use for patients.

The development of personalized medicine is also at the forefront of the use of nanotechnology. By leveraging patient genetic data, nanotechnology offers the possibility of creating treatments tailored specifically to an individual's genetic profile. This means that drugs can be designed to work most effectively according to each patient's unique biology, promising breakthroughs in more personalized and effective medicine. This personalization of treatment not only increases the likelihood of a successful outcome but also reduces the risk of unwanted side effects.

Finally, nanotechnology has the potential to overcome a major challenge in modern medicine, namely drug resistance. Multidrug resistance is a serious problem in the treatment of chronic diseases and infections, where pathogens or cancer cells adapt to the drugs used, making the treatment ineffective. Nanoparticles can be designed to overcome these resistance mechanisms, either by delivering drugs via alternative pathways that are not easily blocked by resistance mechanisms or by carrying multiple therapeutic agents at once to overcome multiple resistance mechanisms simultaneously. Through this approach, nanotechnology offers new hope in the fight against drug resistance, paving the way for more effective therapies against previously difficult-to-treat diseases.

Through all these advances, nanotechnology promises to overcome some of the most significant limitations in drug development and delivery, opening a new era in more effective, personalized, and safe medicine. However, achieving the full potential of these innovations requires ongoing research and development, as well as collaboration between scientists, industry, and regulators to ensure that these new technologies can be accessed safely and effectively by those who need them.

C. Strategies to Overcome the Challenges of Nanometer Scale Drug Synthesis

To overcome the challenges faced in nanometer-scale drug synthesis, a comprehensive and innovative strategy is the main key. One of the most promising approaches is the development of new synthesis methods that are not only efficient and repeatable but also more environmentally friendly. Research in this area continues to develop, with a focus on creating processes that reduce the use of harmful solvents and minimize waste while ensuring that the

resulting nanoparticles have consistent size, shape, and function. Methods such as green synthesis using materials from natural sources or processes that minimize environmental impact are becoming increasingly important. This not only helps in reducing the carbon footprint of the drug manufacturing process but also ensures sustainability in nanometer drug development.

Additionally, advances in characterization techniques play an important role in addressing the challenges of nanometer-scale drug synthesis. A deeper understanding of the physicochemical properties of nanoparticles allows researchers to better control and optimize drug performance. Advanced techniques such as high-resolution mass spectroscopy, electron microscopy, and atomic force imaging have become invaluable tools in visualizing and understanding the structure and dynamics of nanoparticles. With the ability to accurately characterize nanoparticles, scientists can ensure that they have the right attributes for therapeutic applications, from stability to bioavailability.

Interdisciplinary collaboration is also a crucial factor in overcoming the complexity of nanometer-scale drug development. Collaboration between chemists, biologists, physicists, and engineers enables rich knowledge exchange and accelerates innovation. For example, a molecular biologist's knowledge of cellular mechanisms can help in the design of more effective drug delivery systems, while a materials physicist can provide insight into how best to synthesize and manipulate nanoparticles. This collaboration not only increases research efficiency but also expands the potential application of nanometer medicine in medicine.

Finally, supporting policies and regulations are very important in ensuring that innovation in nanometer drug development can develop well. Regulation that is fair and supports innovation can encourage research and development, providing a strong foundation for clinical trials and ultimately, drug approval. Additionally, providing incentives for research and development in this field could stimulate investment from the private sector, speeding the process from discovery to clinical application. Policies that facilitate cooperation between countries and across sectors are also important to fully exploit the global potential of nanotechnology in drug development.

Through this combination of strategies, from the sustainable development of new synthesis methods to policies that support innovation, the scientific community and regulators can together overcome existing challenges and pave the way for a future of more effective and personalized medicine through nanometer-scale medicine.

D. The Future and Hope for Nanometer Scale Medicine

The future of nanometer-scale medicine promises to revolutionize the way we approach treatment and therapy for a variety of diseases, especially those currently considered difficult or even impossible to treat. Advances in nanometer-scale drug synthesis open the door to the development of new, highly effective therapies that can specifically target disease-causing cells or pathogens without damaging surrounding healthy tissue. This is potentially revolutionary in the treatment of cancer, neurodegenerative diseases such as Alzheimer's and Parkinson's, as well as infectious diseases that have shown resistance to antibiotics. With the ability to design drugs at the molecular level, scientists can develop therapies that are not only more effective but also have fewer side effects compared to conventional treatment methods.

In addition to increasing efficacy, innovations in nanotechnology also have great potential in increasing access and sustainability of drug production. With more efficient and sustainable synthesis methods, drug production can be done at lower costs, making them more affordable and accessible to the global population. This is critical in fighting health inequalities around the world, where access to effective and affordable medicines remains a major challenge. Sustainability of production also means that drug manufacturing will have a lower environmental impact, in line with global goals for sustainable development and environmental conservation.

However, along with these advances, it is important to consider ethical and safety aspects in the development of nanometer drugs. The long-term implications of introducing nanoparticles into the human body still need to be fully understood, requiring rigorous clinical studies and trials. Issues such as toxicity, immunogenicity, and potential accumulation of nanoparticles in organisms need to be addressed to ensure that nanometer drugs are not only effective but also safe for long-term use. Ethics in the use of this technology also demands transparency in research and development, as well as consideration of equal access to the resulting therapies.

In a global context, collaboration and knowledge exchange are the keys to maximizing the potential of nanometer-scale medicine for the welfare of humanity. Collaboration between researchers, the pharmaceutical industry, and regulators in different countries can accelerate the discovery and development of new drugs while ensuring that high safety and ethical standards are maintained. The exchange of knowledge and technology also allows countries with limited resources to take advantage of advances in nanotechnology, expanding access to innovative therapies and improving global health. With close international cooperation, we can overcome barriers to drug development and harness the full potential of nanotechnology to create a brighter health future for all.

E. CONCLUSION

Advances in nanometer-scale drug synthesis have paved the way for revolutionary innovations in the pharmaceutical field, promising higher drug efficacy, more precise delivery systems, and the development of more effective personalized therapies. Through exploring strategies to overcome the challenges of synthesis and characterization, as well as harnessing the potential of interdisciplinary collaboration, we are on the verge of creating new therapies that could change the treatment paradigm for chronic diseases and drug resistance. Meanwhile, the potential to increase access and sustainability in drug production promises significant improvements in global health and equitable access to innovative and effective therapies. However, this success also requires us to proactively address the ethical, safety, and regulatory issues that accompany the use of nanometer technology in medicine. Developing policies that support innovation while ensuring patient safety and environmental sustainability will be key. With global collaboration and close knowledge exchange between researchers, industry, and regulators, we can optimize the benefits of nanotechnology for human health, ensuring that these advances not only push the boundaries of science but also improve the quality of life globally. In conclusion, the future of nanometer-scale medicine offers great promise but requires a careful and collaborative approach to realize its full potential for humanity.

REFERENCES

1. Abid, N., Khan, A. M., Shujait, S., Chaudhary, K., Ikram, M., Imran, M., ... & Maqbool, M. (2022). Synthesis of nanomaterials using various top-down and bottom-up approaches, influencing factors, advantages, and disadvantages: A review. Advances in Colloid and Interface Science, 300, 102597.
2. Alsaiari, N. S., Alzahrani, F. M., Amari, A., Osman, H., Harharah, H. N., Elboughdiri, N., & Tahoon, M. A. (2023). Plant and microbial approaches as green methods for the synthesis of nanomaterials: synthesis, applications, and future perspectives. Molecules, 28(1), 463.
3. Bahrulolum, H., Nooraei, S., Javanshir, N., Tarrahimofrad, H., Mirbagheri, V. S., Easton, A. J., & Ahmadian, G. (2021). Green synthesis of metal nanoparticles using microorganisms and their application in the agrifood sector. Journal of Nanobiotechnology, 19, 1-26.

4. Barhoum, A., García-Betancourt, M. L., Jeevanandam, J., Hussien, E. A., Mekkawy, S. A., Mostafa, M., ... & Bechelany, M. (2022). Review on natural, incidental, bioinspired, and engineered nanomaterials: history, definitions, classifications, synthesis, properties, market, toxicities, risks, and regulations. Nanomaterials, 12(2), 177.
5. Bell, E. L., Finnigan, W., France, S. P., Green, A. P., Hayes, M. A., Hepworth, L. J., ... & Flitsch, S. L. (2021). Biocatalysis. Nature Reviews Methods Primers, 1(1), 1-21.
6. Coughlan, C., Bruce, K. D., Burgy, O., Boyd, T. D., Michel, C. R., Garcia-Perez, J. E., ... & Potter, H. (2020). Exosome isolation by ultracentrifugation and precipitation and techniques for downstream analyses. Current Protocols in Cell Biology, 88(1), e110.
7. Dawson, K. A., & Yan, Y. (2021). Current understanding of biological identity at the nanoscale and future prospects. Nature nanotechnology, 16(3), 229-242.
8. Escudero, A., Carrillo-Carrión, C., Romero-Ben, E., Franco, A., Rosales-Barrios, C., Castillejos, M. C., & Khiar, N. (2021). Molecular bottom-up approaches for the synthesis of inorganic and hybrid nanostructures. Inorganics, 9(7), 58.
9. Ijaz, I., Gilani, E., Nazir, A., & Bukhari, A. (2020). Detail review on chemical, physical and green synthesis, classification, characterizations and applications of nanoparticles. Green Chemistry Letters and Reviews, 13(3), 223-245.
10. Khan, Y., Sadia, H., Ali Shah, S. Z., Khan, M. N., Shah, A. A., Ullah, N., ... & Khan, M. I. (2022). Classification, synthetic, and characterization approaches to nanoparticles, and their applications in various fields of nanotechnology: A review. Catalysts, 12(11), 1386.
11. Li, G., Lou, M., & Qi, X. (2022). A brief overview of classical natural product drug synthesis and bioactivity. Organic Chemistry Frontiers, 9(2), 517-571.
12. Liu, G., Yang, G., Peng, X., Wu, J., & Tsubaki, N. (2022). Recent advances in the routes and catalysts for ethanol synthesis from syngas. Chemical Society Reviews, 51(13), 5606-5659.
13. Lovato, K., Fier, P. S., & Maloney, K. M. (2021). The application of modern reactions in large-scale synthesis. Nature Reviews Chemistry, 5(8), 546-563.
14. Malik, S., Muhammad, K., & Waheed, Y. (2023). Nanotechnology: A revolution in modern industry. Molecules, 28(2), 661.
15. Ndolomingo, M. J., Bingwa, N., & Meijboom, R. (2020). Review of supported metal nanoparticles: synthesis methodologies, advantages and application as catalysts. Journal of Materials Science, 55(15), 6195-6241.
16. Pala, R., Anju, V. T., Dyavaiah, M., Busi, S., & Nauli, S. M. (2020). Nanoparticle-mediated drug delivery for the treatment of cardiovascular diseases. International Journal of Nanomedicine, 3741-3769.
17. Park, H., Otte, A., & Park, K. (2022). Evolution of drug delivery systems: From 1950 to 2020 and beyond. Journal of Controlled Release, 342, 53-65.
18. Patti, A., & Sanfilippo, C. (2020). Breaking molecular symmetry through biocatalytic reactions to gain access to valuable chiral synthons. Symmetry, 12(9), 1454.
19. Rogge, T., Kaplaneris, N., Chatani, N., Kim, J., Chang, S., Punji, B., ... & Ackermann, L. (2021). C–H activation. Nature Reviews Methods Primers, 1(1), 43.
20. Sahu, T., Ratre, Y. K., Chauhan, S., Bhaskar, L. V. K. S., Nair, M. P., & Verma, H. K. (2021). Nanotechnology based drug delivery system: Current strategies and emerging therapeutic potential for medical science. Journal of Drug Delivery Science and Technology, 63, 102487.
21. Salvador, M., Gutiérrez, G., Noriega, S., Moyano, A., Blanco-López, M. C., & Matos, M. (2021). Microemulsion synthesis of superparamagnetic nanoparticles for bioapplications. International Journal of Molecular Sciences, 22(1), 427.
22. Szczyglewska, P., Feliczak-Guzik, A., & Nowak, I. (2023). Nanotechnology–general aspects: A chemical reduction approach to the synthesis of nanoparticles. Molecules, 28(13), 4932.

23. Turcheniuk, K., Bondarev, D., Amatucci, G. G., & Yushin, G. (2021). Battery materials for low-cost electric transportation. Materials Today, 42, 57-72.
24. Wainwright, C. L., Teixeira, M. M., Adelson, D. L., Braga, F. C., Buenz, E. J., Campana, P. R., ... & Wolfender, J. L. (2022). Future directions for the discovery of natural product-derived immunomodulating drugs: An IUPHAR positional review. Pharmacological research, 177, 106076.
25. Zhang, L., Song, J., Kong, L., Yuan, T., Li, W., Zhang, W., ... & Du, G. (2020). The strategies and techniques of drug discovery from natural products. Pharmacology & Therapeutics, 216, 107686.